GT Biopharma files 8-K regarding ESMO 2021 presentation; no financial results disclosed

GT Biopharma, Inc.

Dr. Jeffrey Miller presented on GT Biopharma's drug candidates at ESMO Congress 2021.
Updated corporate presentation posted to website as of Sept 20, 2021.
No specific clinical data or financial figures included in this filing.

item 8.01 item 9.01

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-21-010321

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.